Oric Pharmaceuticals, INC Form 4 insider transactions

Lori Anne Kunkel, a director of Oric Pharmaceuticals, acquired 35,000 stock options on January 2, 2025, at an exercise price of $8.26.

Director Steven L. Hoerter acquired 35,000 stock options in Oric Pharmaceuticals on January 2, 2025, according to a Form 4 filing.

Director Richard A. Heyman acquired 35,000 stock options in Oric Pharmaceuticals on January 2, 2025, according to a Form 4 filing.

Director Mardi Dier acquired 35,000 stock options in Oric Pharmaceuticals, vesting monthly over the next year.

Pratik S. Multani, Chief Medical Officer of Oric Pharmaceuticals, acquired stock options for 202,500 shares and 34,000 restricted stock units on January 2, 2025.

Chief Financial Officer of Oric Pharmaceuticals, Dominic Piscitelli, received stock options for 202,500 shares and 34,000 restricted stock units on January 2, 2025.

CEO Jacob Chacko reports the acquisition of stock options and restricted stock units in Oric Pharmaceuticals.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, sold 8,851 shares to cover tax obligations following the vesting of restricted stock units.

Oric Pharmaceuticals' Chief Medical Officer, Pratik S. Multani, executed stock transactions involving the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Oric Pharmaceuticals CEO, Jacob Chacko, exercised stock options and sold shares to cover tax obligations, while also acquiring shares through stock plan.

Director Angie You acquired stock options for 25,600 shares of Oric Pharmaceuticals on June 12, 2024.

Director Lori Anne Kunkel reports the acquisition of stock options in Oric Pharmaceuticals.

Director Steven L. Hoerter acquired 25,600 stock options in Oric Pharmaceuticals on June 12, 2024, according to a Form 4 filing.

Director Dier Mardi acquired 25,600 stock options in Oric Pharmaceuticals on June 12, 2024.

Director Richard A. Heyman acquired stock options in Oric Pharmaceuticals, Inc. on June 12, 2024.

Lori Anne Kunkel, a director at Oric Pharmaceuticals, exercised stock options to acquire 20,500 shares of common stock at $3.75 per share on June 3, 2024.

Oric Pharmaceuticals' CEO, Jacob Chacko, sold 40,000 shares of common stock on March 6, 2024, at a weighted average price of $16.2095.